Rameen Beroukhim
#142,560
Most Influential Person Now
Researcher
Rameen Beroukhim's AcademicInfluence.com Rankings
Rameen Beroukhimengineering Degrees
Engineering
#5407
World Rank
#6665
Historical Rank
Biomedical Engineering
#406
World Rank
#415
Historical Rank
Applied Physics
#1558
World Rank
#1590
Historical Rank
Electrical Engineering
#1500
World Rank
#1594
Historical Rank
Download Badge
Engineering
Rameen Beroukhim's Degrees
- PhD Biomedical Engineering Stanford University
- Masters Electrical Engineering Stanford University
- Bachelors Electrical Engineering University of California, Berkeley
Why Is Rameen Beroukhim Influential?
(Suggest an Edit or Addition)Rameen Beroukhim's Published Works
Number of citations in a given year to any of this author's works
Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author
Published Works
- Comprehensive molecular portraits of human breast tumors (2012) (7791)
- Comprehensive molecular characterization of human colon and rectal cancer (2012) (6141)
- Comprehensive genomic characterization defines human glioblastoma genes and core pathways (2008) (5775)
- Comprehensive molecular characterization of gastric adenocarcinoma (2014) (4496)
- Comprehensive molecular profiling of lung adenocarcinoma (2014) (4095)
- Integrated genomic characterization of endometrial carcinoma (2013) (3708)
- The Somatic Genomic Landscape of Glioblastoma (2013) (3693)
- The landscape of somatic copy-number alteration across human cancers (2010) (3297)
- Comprehensive genomic characterization of squamous cell lung cancers (2012) (2998)
- Comprehensive genomic characterization of head and neck squamous cell carcinomas (2015) (2860)
- The Immune Landscape of Cancer (2018) (2766)
- GISTIC2.0 facilitates sensitive and confident localization of the targets of focal somatic copy-number alteration in human cancers (2011) (2261)
- Comprehensive, Integrative Genomic Analysis of Diffuse Lower-Grade Gliomas. (2015) (2211)
- Genomic Classification of Cutaneous Melanoma (2015) (2143)
- The Molecular Taxonomy of Primary Prostate Cancer (2015) (2116)
- Integrated Genomic Characterization of Papillary Thyroid Carcinoma (2014) (2007)
- Comprehensive molecular characterization of urothelial bladder carcinoma (2014) (1748)
- Comprehensive molecular characterization of clear cell renal cell carcinoma (2013) (1724)
- Oncogenic Signaling Pathways in The Cancer Genome Atlas (2018) (1646)
- Absolute quantification of somatic DNA alterations in human cancer (2012) (1607)
- Comprehensive and Integrative Genomic Characterization of Hepatocellular Carcinoma (2017) (1514)
- Pan-cancer patterns of somatic copy-number alteration (2013) (1501)
- Molecular Profiling Reveals Biologically Discrete Subsets and Pathways of Progression in Diffuse Glioma (2016) (1474)
- Integrative genomic analyses identify MITF as a lineage survival oncogene amplified in malignant melanoma (2005) (1458)
- Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors. (2005) (1455)
- Molecular definition of breast tumor heterogeneity. (2007) (1415)
- Comprehensive Characterization of Cancer Driver Genes and Mutations (2018) (1360)
- Comprehensive Molecular Portraits of Invasive Lobular Breast Cancer (2015) (1332)
- Molecular characterization of the tumor microenvironment in breast cancer. (2004) (1287)
- Sequence analysis of mutations and translocations across breast cancer subtypes (2012) (1133)
- Characterizing the cancer genome in lung adenocarcinoma (2007) (1122)
- Integrated Genomic Characterization of Pancreatic Ductal Adenocarcinoma. (2017) (1092)
- Assessing the significance of chromosomal aberrations in cancer: Methodology and application to glioma (2007) (1052)
- High-throughput oncogene mutation profiling in human cancer (2007) (1041)
- Molecular subtypes of diffuse large B cell lymphoma are associated with distinct pathogenic mechanisms and outcomes (2018) (974)
- Amplification of phosphoglycerate dehydrogenase diverts glycolytic flux and contributes to oncogenesis (2011) (942)
- Comprehensive Molecular Characterization of Papillary Renal-Cell Carcinoma. (2016) (931)
- SOX2 Is an Amplified Lineage Survival Oncogene in Lung and Esophageal Squamous Cell Carcinomas (2009) (904)
- Androgen Receptor Regulates a Distinct Transcription Program in Androgen-Independent Prostate Cancer (2009) (891)
- Frequent and Focal FGFR1 Amplification Associates with Therapeutically Tractable FGFR1 Dependency in Squamous Cell Lung Cancer (2010) (841)
- Distinct patterns of somatic genome alterations in lung adenocarcinomas and squamous cell carcinomas (2016) (826)
- Integrated genomic and molecular characterization of cervical cancer (2017) (762)
- Subgroup-specific structural variation across 1,000 medulloblastoma genomes (2012) (760)
- Genomic Characterization of Brain Metastases Reveals Branched Evolution and Potential Therapeutic Targets. (2015) (727)
- Exome and whole genome sequencing of esophageal adenocarcinoma identifies recurrent driver events and mutational complexity (2013) (700)
- The whole-genome landscape of medulloblastoma subtypes (2017) (658)
- Subtype-specific genomic alterations define new targets for soft tissue sarcoma therapy (2010) (653)
- Genome sequencing of SHH medulloblastoma predicts genotype-related response to smoothened inhibition. (2014) (601)
- Genomic and Functional Approaches to Understanding Cancer Aneuploidy. (2018) (578)
- Comprehensive and Integrated Genomic Characterization of Adult Soft Tissue Sarcomas (2017) (577)
- The evolutionary history of 2,658 cancers (2017) (575)
- β-Catenin-Driven Cancers Require a YAP1 Transcriptional Complex for Survival and Tumorigenesis (2012) (557)
- Highly parallel identification of essential genes in cancer cells (2008) (553)
- TMPRSS2:ERG fusion-associated deletions provide insight into the heterogeneity of prostate cancer. (2006) (539)
- Genetic and transcriptional evolution alters cancer cell line drug response (2018) (536)
- Pathogenic Germline Variants in 10,389 Adult Cancers (2018) (501)
- Genomic sequencing of meningiomas identifies oncogenic SMO and AKT1 mutations (2013) (497)
- The Cancer Genome Atlas Comprehensive Molecular Characterization of Renal Cell Carcinoma (2018) (480)
- Comprehensive Analysis of Alternative Splicing Across Tumors from 8,705 Patients (2018) (471)
- The histone methyltransferase SETDB1 is recurrently amplified in melanoma and accelerates its onset (2011) (471)
- Integrative molecular analysis of intrahepatic cholangiocarcinoma reveals 2 classes that have different outcomes. (2013) (418)
- Somatic Activation of AKT3 Causes Hemispheric Developmental Brain Malformations (2012) (396)
- Patterns of gene expression and copy-number alterations in von-hippel lindau disease-associated and sporadic clear cell carcinoma of the kidney. (2009) (392)
- An oncogene–tumor suppressor cascade drives metastatic prostate cancer by coordinately activating Ras and nuclear factor-κB (2010) (392)
- Patterns of somatic structural variation in human cancer genomes (2020) (377)
- Patterns of somatic structural variation in human cancer genomes (2020) (377)
- Patterns of somatic structural variation in human cancer genomes (2020) (377)
- Patient-derived xenografts undergo murine-specific tumor evolution (2017) (375)
- Developmental and oncogenic programs in H3K27M gliomas dissected by single-cell RNA-seq (2018) (368)
- Genetic and functional studies implicate HIF1α as a 14q kidney cancer suppressor gene. (2011) (356)
- Lin28 Enhances Tumorigenesis and is Associated With Advanced Human Malignancies (2009) (349)
- Oncosome formation in prostate cancer: association with a region of frequent chromosomal deletion in metastatic disease. (2009) (349)
- Epidermal Growth Factor Receptor Activation in Glioblastoma through Novel Missense Mutations in the Extracellular Domain (2006) (345)
- Homozygous deletions and chromosome amplifications in human lung carcinomas revealed by single nucleotide polymorphism array analysis. (2005) (341)
- Genome coverage and sequence fidelity of phi29 polymerase-based multiple strand displacement whole genome amplification. (2004) (318)
- Modeling genomic diversity and tumor dependency in malignant melanoma. (2008) (294)
- BET Bromodomain Inhibition of MYC-Amplified Medulloblastoma (2013) (281)
- Predicting drug susceptibility of non-small cell lung cancers based on genetic lesions. (2009) (275)
- Integrated genomic profiling of endometrial carcinoma associates aggressive tumors with indicators of PI3 kinase activation (2009) (274)
- β-Catenin-Driven Cancers Require a YAP1 Transcriptional Complex for Survival and Tumorigenesis (2013) (268)
- Integrated Genome-Wide DNA Copy Number and Expression Analysis Identifies Distinct Mechanisms of Primary Chemoresistance in Ovarian Carcinomas (2009) (265)
- Gastrointestinal adenocarcinomas of the esophagus, stomach, and colon exhibit distinct patterns of genome instability and oncogenesis. (2012) (260)
- Epigenetic targeting of Hedgehog pathway transcriptional output through BET bromodomain inhibition (2014) (256)
- Mechanisms and therapeutic implications of hypermutation in gliomas (2020) (256)
- Identifying genotype-dependent efficacy of single and combined PI3K- and MAPK-pathway inhibition in cancer (2009) (254)
- Tumor suppressor genes that escape from X-inactivation contribute to cancer sex bias (2016) (244)
- Predicting clinical response to anticancer drugs using an ex vivo platform that captures tumour heterogeneity (2015) (240)
- Bead-based profiling of tyrosine kinase phosphorylation identifies SRC as a potential target for glioblastoma therapy (2009) (229)
- SvABA: genome-wide detection of structural variants and indels by local assembly (2017) (226)
- LONGITUDINAL MOLECULAR TRAJECTORIES OF DIFFUSE GLIOMA IN ADULTS (2019) (223)
- Structural Alterations Driving Castration-Resistant Prostate Cancer Revealed by Linked-Read Genome Sequencing (2018) (221)
- Analyses of non-coding somatic drivers in 2,658 cancer whole genomes (2020) (220)
- Analyses of non-coding somatic drivers in 2,658 cancer whole genomes (2020) (220)
- Histone demethylase KDM6A directly senses oxygen to control chromatin and cell fate (2019) (209)
- Oncogenic PI3K mutations are as common as AKT1 and SMO mutations in meningioma. (2016) (202)
- Comprehensive molecular characterization of mitochondrial genomes in human cancers (2017) (197)
- Cancer Vulnerabilities Unveiled by Genomic Loss (2012) (195)
- Long-Term Outcome of 4,040 Children Diagnosed With Pediatric Low-Grade Gliomas: An Analysis of the Surveillance Epidemiology and End Results (SEER) Database (2014) (192)
- Integrative analysis reveals an outcome-associated and targetable pattern of p53 and cell cycle deregulation in diffuse large B cell lymphoma. (2012) (190)
- Pan-Cancer Analysis of lncRNA Regulation Supports Their Targeting of Cancer Genes in Each Tumor Context (2018) (188)
- MYB-QKI rearrangements in Angiocentric Glioma drive tumorigenicity through a tripartite mechanism (2016) (185)
- Treatment-Induced Tumor Dormancy through YAP-Mediated Transcriptional Reprogramming of the Apoptotic Pathway. (2020) (184)
- Recurrent Hemizygous Deletions in Cancers May Optimize Proliferative Potential (2012) (181)
- Pan-cancer analysis of whole genomes identifies driver rearrangements promoted by LINE-1 retrotransposition (2020) (180)
- Pan-cancer analysis of whole genomes identifies driver rearrangements promoted by LINE-1 retrotransposition (2020) (180)
- Genomic analysis of diffuse pediatric low-grade gliomas identifies recurrent oncogenic truncating rearrangements in the transcription factor MYBL1 (2013) (180)
- Inferring Loss-of-Heterozygosity from Unpaired Tumors Using High-Density Oligonucleotide SNP Arrays (2006) (177)
- High‐resolution genomic and expression analyses of copy number alterations in breast tumors (2008) (170)
- The genomic landscape and evolution of endometrial carcinoma progression and abdominopelvic metastasis (2016) (168)
- Interpreting cancer genomes using systematic host perturbations by tumour virus proteins (2012) (167)
- Oncogenic PIK3CA-driven mammary tumors frequently recur via PI3K pathway-dependent and -independent mechanisms (2011) (166)
- Characterizing genetic intra-tumor heterogeneity across 2,658 human cancer genomes (2020) (166)
- Characterizing genetic intra-tumor heterogeneity across 2,658 human cancer genomes (2020) (166)
- Overexpression, Amplification, and Androgen Regulation of TPD52 in Prostate Cancer (2004) (159)
- Chemical genomics identifies small-molecule MCL1 repressors and BCL-xL as a predictor of MCL1 dependency. (2012) (158)
- Proteasomal and genetic inactivation of the NF1 tumor suppressor in gliomagenesis. (2009) (149)
- Pan-cancer genetic analysis identifies PARK2 as a master regulator of G1/S cyclins (2014) (148)
- Medical therapies for meningiomas (2010) (147)
- Abstract 1028: Patient-derived xenografts undergo mouse-specific tumor evolution (2018) (147)
- An in-tumor genetic screen reveals that the BET bromodomain protein, BRD4, is a potential therapeutic target in ovarian carcinoma (2014) (146)
- SQSTM1 is a pathogenic target of 5q copy number gains in kidney cancer. (2013) (137)
- Genomic evolution of cancer models: perils and opportunities (2018) (136)
- The Somatic Genomic Landscape of Glioblastoma (2014) (135)
- Molecular characterization of TMPRSS2-ERG gene fusion in the NCI-H660 prostate cancer cell line: a new perspective for an old model. (2007) (134)
- PAK1 is a breast cancer oncogene that coordinately activates MAPK and MET signaling (2011) (133)
- Targeting wild-type KRAS amplified gastroesophageal cancer through combined MEK and SHP2 (2018) (133)
- Genomic landscape of high-grade meningiomas (2017) (132)
- Somatic rearrangements across cancer reveal classes of samples with distinct patterns of DNA breakage and rearrangement-induced hypermutability (2012) (132)
- Oncogenic PIK 3 CA-driven mammary tumors frequently recur via PI 3 K pathway – dependent and PI 3 K pathway – independent mechanisms (2011) (132)
- Disruption of chromatin folding domains by somatic genomic rearrangements in human cancer (2020) (128)
- Extent of resection and overall survival for patients with atypical and malignant meningioma (2015) (128)
- Allele-Specific Amplification in Cancer Revealed by SNP Array Analysis (2005) (128)
- SGK3 mediates INPP4B-dependent PI3K signaling in breast cancer. (2014) (127)
- ATARiS: Computational quantification of gene suppression phenotypes from multisample RNAi screens (2013) (124)
- Ultrastructure of the 5‐Hydroxytryptamine3 Receptor (1995) (124)
- Coordinate activation of Shh and PI3K signaling in PTEN-deficient glioblastoma: new therapeutic opportunities (2013) (123)
- Cas9 activates the p53 pathway and selects for p53-inactivating mutations (2020) (123)
- ERG rearrangement is specific to prostate cancer and does not occur in any other common tumor (2010) (121)
- Genomic evolution and chemoresistance in germ-cell tumours (2016) (118)
- The RasGAP gene, RASAL2, is a tumor and metastasis suppressor. (2013) (115)
- Single nucleotide polymorphism array analysis of cancer (2007) (113)
- Germline and somatic BAP1 mutations in high-grade rhabdoid meningiomas (2016) (113)
- A mathematical framework to determine the temporal sequence of somatic genetic events in cancer (2010) (110)
- Comprehensive Analysis of Genetic Ancestry and Its Molecular Correlates in Cancer. (2020) (105)
- Erratum : The Cancer Genome Atlas Comprehensive Molecular Characterization of Renal Cell Carcinoma (Cell Reports (2018) 23(1) (313–326.e5) (S2211124718304364) (10.1016/j.celrep.2018.03.075)) (2018) (103)
- Glioma through the looking GLASS: molecular evolution of diffuse gliomas and the Glioma Longitudinal Analysis Consortium (2018) (102)
- The genomic landscape of schwannoma (2016) (97)
- Integrative pathway enrichment analysis of multivariate omics data (2018) (96)
- Three-dimensional location of the main immunogenic region of the acetylcholine receptor (1995) (95)
- Phase II study of panobinostat in combination with bevacizumab for recurrent glioblastoma and anaplastic glioma. (2015) (94)
- Radiographic prediction of meningioma grade by semantic and radiomic features (2017) (93)
- Distinct genomic aberrations associated with ERG rearranged prostate cancer (2009) (93)
- Distinct Classes of Complex Structural Variation Uncovered across Thousands of Cancer Genome Graphs (2020) (90)
- Erratum: Integrative Genomic Analysis of Cholangiocarcinoma Identifies Distinct IDH-Mutant Molecular Profiles (Cell Reports (2017) 18(11) (2780–2794) (S2211124717302140) (10.1016/j.celrep.2017.02.033)) (2017) (88)
- Amplification of chromosomal segment 4q12 in non-small cell lung cancer (2009) (87)
- Characterizing genomic alterations in cancer by complementary functional associations (2016) (86)
- The Cancer Genome Atlas Comprehensive Molecular Characterization of Renal Cell Carcinoma. (2018) (86)
- Aneuploidy renders cancer cells vulnerable to mitotic checkpoint inhibition (2021) (86)
- Adjuvant radiation therapy, local recurrence, and the need for salvage therapy in atypical meningioma. (2014) (85)
- Systematic screening reveals a role for BRCA1 in the response to transcription-associated DNA damage (2014) (84)
- Genomic landscape of intracranial meningiomas. (2016) (83)
- Cancer LncRNA Census reveals evidence for deep functional conservation of long noncoding RNAs in tumorigenesis (2020) (80)
- Safety of concurrent bevacizumab therapy and anticoagulation in glioma patients (2011) (79)
- Exome sequencing of lymphomas from three dog breeds reveals somatic mutation patterns reflecting genetic background (2015) (78)
- Landscape of Genomic Alterations in Pituitary Adenomas (2016) (78)
- Phase 2 study of dose-intense temozolomide in recurrent glioblastoma. (2013) (77)
- Prospective Analysis of Adoptive TIL Therapy in Patients with Metastatic Melanoma: Response, Impact of Anti-CTLA4, and Biomarkers to Predict Clinical Outcome (2018) (77)
- Phase I study of panobinostat in combination with bevacizumab for recurrent high-grade glioma (2012) (76)
- Buparlisib in Patients With Recurrent Glioblastoma Harboring Phosphatidylinositol 3-Kinase Pathway Activation: An Open-Label, Multicenter, Multi-Arm, Phase II Trial. (2019) (75)
- The SETDB1 histone methyltransferase is recurrently amplified in and accelerates melanoma (2011) (75)
- Integrated Genomic Analysis of the 8q24 Amplification in Endometrial Cancers Identifies ATAD2 as Essential to MYC-Dependent Cancers (2013) (74)
- Systematic interrogation of 3q26 identifies TLOC1 and SKIL as cancer drivers. (2013) (73)
- ARID1A and TERT promoter mutations in dedifferentiated meningioma. (2015) (71)
- A Multicenter, Phase II, Randomized, Noncomparative Clinical Trial of Radiation and Temozolomide with or without Vandetanib in Newly Diagnosed Glioblastoma Patients (2015) (68)
- A prognostic cytogenetic scoring system to guide the adjuvant management of patients with atypical meningioma. (2015) (67)
- Copy-number and gene dependency analysis reveals partial copy loss of wild-type SF3B1 as a novel cancer vulnerability (2017) (67)
- Distortion correction of tubular crystals: improvements in the acetylcholine receptor structure. (1997) (65)
- SNP panel identification assay (SPIA): a genetic-based assay for the identification of cell lines (2008) (64)
- Clinical targeted exome-based sequencing in combination with genome-wide copy number profiling: precision medicine analysis of 203 pediatric brain tumors (2017) (63)
- Retrospective study of dasatinib for recurrent glioblastoma after bevacizumab failure (2011) (63)
- Structure and mechanism of activity-based inhibition of the EGF-Receptor by Mig6 (2015) (61)
- Histone H3.3G34-Mutant Interneuron Progenitors Co-opt PDGFRA for Gliomagenesis (2020) (61)
- Pediatric low-grade gliomas: how modern biology reshapes the clinical field. (2014) (61)
- MicroRNA Signatures and Molecular Subtypes of Glioblastoma: The Role of Extracellular Transfer (2017) (58)
- Angiomatous meningiomas have a distinct genetic profile with multiple chromosomal polysomies including polysomy of chromosome 5 (2014) (58)
- A Mathematical Methodology for Determining the Temporal Order of Pathway Alterations Arising during Gliomagenesis (2012) (57)
- Phase II study of monthly pasireotide LAR (SOM230C) for recurrent or progressive meningioma (2015) (55)
- Beating the odds: extreme long-term survival with glioblastoma. (2014) (55)
- Amplification and overexpression of prosaposin in prostate cancer (2005) (54)
- Clinical multiplexed exome sequencing distinguishes adult oligodendroglial neoplasms from astrocytic and mixed lineage gliomas (2014) (53)
- In vivo multiplexed interrogation of amplified genes identifies GAB2 as an ovarian cancer oncogene (2014) (53)
- Disseminated glioneuronal tumors occurring in childhood: treatment outcomes and BRAF alterations including V600E mutation (2016) (51)
- TRAF2 is an NF-κB activating oncogene in epithelial cancers (2013) (50)
- Molecular profiling of endometrial carcinoma precursor, primary and metastatic lesions suggests different targets for treatment in obese compared to non-obese patients (2014) (50)
- The whole-genome panorama of cancer drivers (2017) (50)
- Erratum: The somatic genomic landscape of glioblastoma (Cell (2013) 155 (462-477)) (2014) (49)
- Patterns of structural variation in human cancer (2017) (48)
- A molecularly integrated grade for meningioma (2021) (47)
- Resistance to Epigenetic-Targeted Therapy Engenders Tumor Cell Vulnerabilities Associated with Enhancer Remodeling. (2018) (46)
- Clinical Identification of Oncogenic Drivers and Copy-Number Alterations in Pituitary Tumors (2017) (46)
- Low BMI-1 expression is associated with an activated BMI-1-driven signature, vascular invasion, and hormone receptor loss in endometrial carcinoma (2008) (46)
- Portraits of genetic intra-tumour heterogeneity and subclonal selection across cancer types (2018) (45)
- MECP2 Is a Frequently Amplified Oncogene with a Novel Epigenetic Mechanism That Mimics the Role of Activated RAS in Malignancy. (2015) (44)
- miR-4516 predicts poor prognosis and functions as a novel oncogene via targeting PTPN14 in human glioblastoma (2018) (42)
- Major copy proportion analysis of tumor samples using SNP arrays (2008) (42)
- Prioritizing causal disease genes using unbiased genomic features (2014) (42)
- Loss of heterozygosity of essential genes represents a widespread class of potential cancer vulnerabilities (2019) (41)
- Clinical implementation of integrated whole-genome copy number and mutation profiling for glioblastoma. (2015) (41)
- Sex differences in oncogenic mutational processes (2019) (41)
- Genomic profile of human meningioma cell lines (2017) (40)
- HER-2/neu expression is associated with high tumor cell proliferation and aggressive phenotype in a population based patient series of endometrial carcinomas. (2008) (39)
- Expression profiles of 151 pediatric low-grade gliomas reveal molecular differences associated with location and histological subtype. (2015) (39)
- Copy number alterations unmasked as enhancer hijackers (2016) (38)
- Integrative analysis reveals 53BP1 copy loss and decreased expression in a subset of human diffuse large B-cell lymphomas (2008) (38)
- Vandetanib plus sirolimus in adults with recurrent glioblastoma: results of a phase I and dose expansion cohort study (2014) (38)
- Myxopapillary ependymomas in children: imaging, treatment and outcomes (2015) (38)
- Molecular profiling and targeted therapy in pediatric gliomas: review and consensus recommendations. (2019) (37)
- Orthotopic xenografts of RCC retain histological, immunophenotypic and genetic features of tumours in patients (2011) (36)
- Tumor Interferon Signaling Is Regulated by a lncRNA INCR1 Transcribed from the PD-L1 Locus. (2020) (36)
- "Lineage addiction" in human cancer: lessons from integrated genomics. (2005) (36)
- Somatic mutations are present in all members of the AKT family in endometrial carcinoma (2009) (35)
- High-coverage whole-genome analysis of 1220 cancers reveals hundreds of genes deregulated by rearrangement-mediated cis-regulatory alterations (2020) (34)
- Somatic copy number alterations in gastric adenocarcinomas among Asian and Western patients (2017) (33)
- Tyrosine receptor kinase B is a drug target in astrocytomas (2017) (32)
- Selective and mechanistic sources of recurrent rearrangements across the cancer genome (2017) (31)
- Author Correction: Targeting wild-type KRAS-amplified gastroesophageal cancer through combined MEK and SHP2 inhibition (2018) (31)
- Interim Analysis of a Phase I/II Study of Panobinostat in Combination with Bevacizumab for Recurrent Glioblastoma (P01.094) (2013) (31)
- Combined burden and functional impact tests for cancer driver discovery using DriverPower (2020) (31)
- Genomic and Epigenomic Landscape in Meningioma. (2016) (30)
- Reconstructing evolutionary trajectories of mutation signature activities in cancer using TrackSig (2020) (30)
- Mitogenic and progenitor gene programmes in single pilocytic astrocytoma cells (2019) (30)
- The design and validation of a novel phenotypic assay to determine HIV-1 coreceptor usage of clinical isolates. (2010) (29)
- Early TP53 Alterations Engage Environmental Exposures to Promote Gastric Premalignancy in an Integrative Mouse Model (2019) (29)
- Neuronal differentiation and cell-cycle programs mediate response to BET-bromodomain inhibition in MYC-driven medulloblastoma (2019) (29)
- Update on bevacizumab and other angiogenesis inhibitors for brain cancer (2013) (28)
- MAPK activation and HRAS mutation identified in pituitary spindle cell oncocytoma (2016) (27)
- Inferring structural variant cancer cell fraction (2020) (27)
- Renal medullary carcinomas depend upon SMARCB1 loss and are sensitive to proteasome inhibition (2018) (26)
- Pan-Cancer Analysis Links PARK2 to BCL-XL-Dependent Control of Apoptosis (2016) (26)
- Genomic Heterogeneity and Exceptional Response to Dual Pathway Inhibition in Anaplastic Thyroid Cancer (2016) (24)
- Retrospective study of carmustine or lomustine with bevacizumab in recurrent glioblastoma patients who have failed prior bevacizumab. (2014) (24)
- Activity of PD-1 blockade with Nivolumab among patients with recurrent atypical/anaplastic meningioma: Phase II trial results. (2021) (24)
- Ancestry-specific predisposing germline variants in cancer (2020) (23)
- Retrospective evaluation of whole exome and genome mutation calls in 746 cancer samples (2020) (22)
- VariantBam: filtering and profiling of next-generational sequencing data using region-specific rules (2016) (21)
- Leveraging molecular datasets for biomarker-based clinical trial design in glioblastoma (2017) (21)
- Pan-cancer analysis of whole genomes reveals driver rearrangements promoted by LINE-1 retrotransposition in human tumours (2017) (19)
- Stathmin is superior to AKT and phospho‐AKT staining for the detection of phosphoinositide 3‐kinase activation and aggressive endometrial cancer (2010) (18)
- Author Correction: Molecular subtypes of diffuse large B cell lymphoma are associated with distinct pathogenic mechanisms and outcomes (2018) (15)
- PIK3CA Amplification Associates with Aggressive Phenotype but Not Markers of AKT-MTOR Signaling in Endometrial Carcinoma (2018) (14)
- Novel patterns of complex structural variation revealed across thousands of cancer genome graphs (2019) (14)
- Recurrent hormone-binding domain truncated ESR1 amplifications in primary endometrial cancers suggest their implication in hormone independent growth (2016) (14)
- Tumor associated seizures in glioblastomas are influenced by survival gene expression in a region-specific manner: A gene expression imaging study (2014) (14)
- Phase II study of dose-intense temozolomide in recurrent glioblastoma. (2011) (13)
- Liquid biopsy detection of genomic alterations in pediatric brain tumors from cell-free DNA in peripheral blood, CSF, and urine. (2022) (13)
- TIRR inhibits the 53BP1-p53 complex to alter cell-fate programs. (2021) (12)
- EPIGENETIC TARGETING OF HEDGEHOG PATHWAY TRANSCRIPTIONAL OUTPUT (2014) (12)
- Frequent and focal FGFR1 amplification associates with therapeutically tractable FGFR1 dependency in squamous cell lung cancer (Science Translational Medicine (2012) 4, (130er2)) (2011) (12)
- Incidence, risk factors, and reasons for hospitalization among glioblastoma patients receiving chemoradiation (2015) (11)
- Case Report: Next generation sequencing identifies a NAB2-STAT6 fusion in Glioblastoma (2016) (11)
- Phase II trial of ponatinib in patients with bevacizumab‐refractory glioblastoma (2019) (11)
- Quantification of aneuploidy in targeted sequencing data using ASCETS (2020) (10)
- Preliminary results from a multicenter, phase II, randomized, noncomparative clinical trial of radiation and temozolomide with or without vandetanib in newly diagnosed glioblastoma (GBM). (2011) (10)
- Erratum: Genomic landscape of high-grade meningiomas (2017) (10)
- Whole-genome characterization of lung adenocarcinomas lacking alterations in the RTK/RAS/RAF pathway (2021) (10)
- CloneSifter: enrichment of rare clones from heterogeneous cell populations (2020) (10)
- MR Imaging Correlates for Molecular and Mutational Analyses in Children with Diffuse Intrinsic Pontine Glioma (2020) (10)
- Abstract 3000: Pervasive intra-tumour heterogeneity and subclonal selection across cancer types (2018) (9)
- Ongoing clinical trials. (2003) (9)
- Phase II study of monthly pasireotide LAR (SOM230C) for recurrent or progressive meningioma. (2011) (8)
- Author Correction: Cas9 activates the p53 pathway and selects for p53-inactivating mutations (2020) (8)
- Structural variants shape driver combinations and outcomes in pediatric high-grade glioma (2021) (8)
- SeqLib: a C ++ API for rapid BAM manipulation, sequence alignment and sequence assembly (2016) (8)
- Erratum: High-throughput oncogene mutation profiling in human cancer (Nature Genetics (2007) 39, (347-351)) (2007) (7)
- PPM1D mutations are oncogenic drivers of de novo diffuse midline glioma formation (2022) (7)
- Erratum: Inferring loss-of-heterozygosity from unpaired tumors using high-density oligonucleotide SNP arrays (PLoS Computational Biology 2, 5, doi:10.1371/journal.pcbi.0020041) (2007) (7)
- Reply to Parsons: Many tumor types follow the monoclonal model of tumor initiation (2011) (7)
- Erratum: Corrigendum: High-throughput oncogene mutation profiling in human cancer (2007) (7)
- The Tangent copy-number inference pipeline for cancer genome analyses (2019) (7)
- DNA-based copy number analysis confirms genomic evolution of PDX models (2021) (7)
- A phase I trial of LBH589 and bevacizumab for recurrent high-grade glioma (HGG). (2011) (7)
- Structure and mechanism of activity-based inhibition of the EGF-Receptor by Mig 6 (2016) (7)
- Publisher Correction: Comprehensive analysis of chromothripsis in 2,658 human cancers using whole-genome sequencing (2020) (6)
- Selective vulnerability of aneuploid human cancer cells to inhibition of the spindle assembly checkpoint (2020) (6)
- Targeting cancer gene dependencies with anthrax-mediated delivery of peptide nucleic acids. (2020) (6)
- Clinical utility of targeted next generation sequencing assay in IDH-wildtype glioblastoma for therapy decision-making. (2021) (6)
- Pan-cancer analysis of whole genomes identifies driver rearrangements promoted by LINE-1 retrotransposition (2020) (6)
- Pan-cancer analysis of whole genomes identifies driver rearrangements promoted by LINE-1 retrotransposition (2020) (6)
- Phase II trial of ponatinib in patients with bevacizumab-refractory glioblastoma. (2018) (5)
- SU-D-207B-02: Early Grade Classification in Meningioma Patients Combining Radiomics and Semantics Data. (2016) (5)
- Spatial Genome Organization as a Framework for Somatic Alterations in Human Cancer (2017) (5)
- 2905 Genomic characterization of brain metastases and paired primary tumors reveals branched evolution and potential therapeutic targets (2015) (5)
- Safety of concurrent bevacizumab therapy and anticoagulation in high-grade glioma patients. (2010) (5)
- CloneSifter: enrichment of rare clones from heterogeneous cell populations (2020) (4)
- Ancestry-specific predisposing germline variants in cancer (2020) (4)
- NEURO/MEDICAL ONCOLOGY (2013) (4)
- Ancestry-specific predisposing germline variants in cancer (2020) (4)
- Genomic Identification of Significant Targets in Brain Cancer (2009) (4)
- Haplotype-resolved germline and somatic alterations in renal medullary carcinomas (2021) (4)
- GENE-07. LIQUID BIOPSY DETECTION OF GENOMIC ALTERATIONS IN PEDIATRIC BRAIN TUMORS FROM CELL-FREE DNA IN PERIPHERAL BLOOD, CSF, AND URINE (2018) (3)
- CloneRetriever: retrieval of rare clones from heterogeneous cell populations (2019) (3)
- The genomic landscape of dysembryoplastic neuroepithelial tumours and a comprehensive analysis of recurrent cases (2022) (3)
- Panobinostat in combination with bevacizumab for recurrent glioblastoma and anaplastic glioma. (2014) (3)
- A phase I study of MLN0128 and bevacizumab in patients with recurrent glioblastoma and other solid tumors. (2016) (3)
- Structural variations in cancer and the 3D genome (2022) (3)
- Abstracts of the 45th Congress of the International Society of Paediatric Oncology (SIOP) 2013. Hong Kong, China. September 25-28, 2013. (2013) (3)
- VRK1 as a synthetic lethal target in VRK2 promoter–methylated cancers of the nervous system (2022) (3)
- Abstract 218: The evolutionary history of 2,658 cancers (2018) (2)
- MCL1 and DEDD Promote Urothelial Carcinoma Progression (2019) (2)
- CTNI-12. PRELIMINARY RESULTS OF THE ABEMACICLIB ARM IN THE INDIVIDUALIZED SCREENING TRIAL OF INNOVATIVE GLIOBLASTOMA THERAPY (INSIGHT): A PHASE II PLATFORM TRIAL USING BAYESIAN ADAPTIVE RANDOMIZATION (2020) (2)
- Phase II study of monthly pasireotide LAR (SOM230C) for recurrent or progressive meningioma: Final results. (2014) (2)
- PDTM-06. ALK AMPLIFICATION AND REARRANGEMENTS ARE RECURRENT TARGETABLE EVENTS IN GLIOBLASTOMA (2018) (2)
- BM-07GENOMIC CHARACTERIZATION OF BRAIN METASTASES REVEALS BRANCHED EVOLUTION AND METASTASIS-SPECIFIC MUTATIONS (2014) (2)
- Inferring Loss-of-Heterozygosity From Tumor-only Samples Using High-Density Oligonucleotide SNP Arrays (2)
- Integrative modeling identifies genetic ancestry-associated molecular correlates in human cancer (2021) (2)
- Genetic and transcriptional evolution alters cancer cell line drug response (2018) (2)
- Neuronal differentiation and cell-cycle programs mediate response to BET-bromodomain inhibition in MYC-driven medulloblastoma (2019) (2)
- CTNI-11. CC-115 IN NEWLY DIAGNOSED MGMT UNMETHYLATED GLIOBLASTOMA IN THE INDIVIDUALIZED SCREENING TRIAL OF INNOVATIVE GLIOBLASTOMA THERAPY (INSIGHT): A PHASE II RANDOMIZED BAYESIAN ADAPTIVE PLATFORM TRIAL (2020) (2)
- Abstract NG03: Genomic characterization of 101 brain metastases and paired primary tumors reveals patterns of clonal evolution and selection of driver mutations (2014) (2)
- CELL BIOLOGY AND SIGNALING (2010) (2)
- The impact of puberty on tumor incidence & progression in childhood low grade glioma (2014) (1)
- Analytical protocol to identify local ancestry-associated molecular features in cancer (2021) (1)
- Polymorphism Array Analysis Human Lung Carcinomas Revealed by Single Nucleotide Homozygous Deletions and Chromosome Amplifications in (2005) (1)
- Supplementary Material 23 (2012) (1)
- Supplementary Material 10 (2014) (1)
- Open data: Spot data glitches before publication (2017) (1)
- EPT-20CLINICAL TARGETED EXOME-BASED SEQUENCING IN COMBINATION WITH GENOME WIDE COPY NUMBER PROFILING: A CLIA CERTIFIED APPROACH FOR PRECISION MEDICINE IN 203 PEDIATRIC BRAIN TUMOR PATIENTS (2016) (1)
- Genomic Correlates of Outcome in Tumor-Infiltrating Lymphocyte Therapy for Metastatic Melanoma. (2022) (1)
- OS08.3 Genomic landscape of meningiomas (2017) (1)
- Malignant Melanoma Modeling Genomic Diversity and Tumor Dependency in Updated (2008) (1)
- Tangent normalization for somatic copy-number inference in cancer genome analysis (2022) (1)
- Prioritizing causal disease genes using unbiased genomic features (2014) (1)
- Combined whole genome copy number genotyping and multiplex somatic mutation profiling of FFPE brain tumor specimens for clinical diagnosis and trial selection. (2013) (1)
- Escape from X-Inactivation Tumor Suppressor (EXITS) Genes Are Associated with Excess Incidence of Cancer in Men (2015) (1)
- Abstract 3003: Loss of heterozygosity of essential genes represents a novel class of cancer vulnerabilities (2018) (1)
- Genetically-Defined Diffuse Large B-Cell Lymphoma Subsets Arise By Distinct Pathogenetic Mechanisms and Predict Outcome (2017) (1)
- OS9.1 Clinical significance of hypermutation in gliomas (2019) (1)
- The oncogene makes its escape (2016) (1)
- BIOM-44. GENOMIC PREDICTORS OF ADVERSE EVENTS IN NEWLY DIAGNOSED IDH-WILDTYPE GLIOBLASTOMA (2020) (1)
- PLOS Medicine 2017 Reviewer and Editorial Board Thank You (2018) (1)
- Cancer Therapy : Preclinical BET Bromodomain Inhibition of MYC-Ampli fi ed Medulloblastoma (2014) (1)
- Targeting wild-type KRAS-amplified gastroesophageal cancer through combined MEK and SHP2 inhibition (2018) (1)
- Abstract 5759: The landscape of copy-number changes across multiple human cancer types (2010) (1)
- Whole-genome characterization of lung adenocarcinomas lacking alterations in the RTK/RAS/RAF pathway (2021) (1)
- Abstract 2352: Defining a pediatric cancer dependency map (2018) (1)
- HGG-41. STRUCTURAL VARIANT DRIVERS IN PEDIATRIC HIGH-GRADE GLIOMA (2020) (1)
- Publisher Correction: Molecular subtypes of diffuse large B cell lymphoma are associated with distinct pathogenic mechanisms and outcomes (2018) (1)
- Analysis of germline-driven ancestry-associated gene expression in cancers (2022) (1)
- Author Correction: Combined burden and functional impact tests for cancer driver discovery using DriverPower (2020) (1)
- Author Correction: Reconstructing evolutionary trajectories of mutation signature activities in cancer using TrackSig (2020) (1)
- GENE-09. PRECISION MEDICINE ANALYSIS OF 203 PEDIATRIC BRAIN TUMORS REVEALS CLINICALLY RELEVANT GENOMIC ALTERATIONS (2017) (1)
- GENE-09. PRECISION MEDICINE ANALYSIS OF 203 PEDIATRIC BRAIN TUMORS REVEALS CLINICALLY RELEVANT GENOMIC ALTERATIONS (2017) (1)
- CTNI-05. PRELIMINARY RESULTS OF THE NERATINIB ARM IN THE INDIVIDUALIZED SCREENING TRIAL OF INNOVATIVE GLIOBLASTOMA THERAPY (INSIGHT): A PHASE II PLATFORM TRIAL USING BAYESIAN ADAPTIVE RANDOMIZATION (2021) (1)
- Distinct copy number alteration patterns as prognostic of endometrial cancer outcomes. (2013) (1)
- GENT-36. THE GENOMIC LANDSCAPE OF SCHWANNOMA (2016) (1)
- Author Correction: Pathway and network analysis of more than 2500 whole cancer genomes (2020) (1)
- Author Correction: Integrative pathway enrichment analysis of multivariate omics data (2020) (1)
- DIPG-29. GENOMIC LANDSCAPE OF DIFFUSE INTRINSIC PONTINE GLIOMA: AN ANALYSIS OF THE DIPG-BATS COHORT (2017) (1)
- ATNT-18A PHASE I STUDY OF MLN0128 AND BEVACIZUMAB IN PATIENTS WITH RECURRENT GLIOBLASTOMA AND OTHER SOLID TUMORS (2015) (1)
- Author Correction: Pan-cancer analysis of whole genomes (2023) (1)
- Disruption of chromatin folding domains by somatic genomic rearrangements in human cancer (2020) (1)
- Mechanisms and therapeutic implications of hypermutation in gliomas (2020) (1)
- Aberrant DNA repair is a vulnerability in histone H3.3-mutant brain tumors (2022) (1)
- Publisher Correction: DNA-based copy number analysis confirms genomic evolution of PDX models (2022) (0)
- HG-73SAFETY AND FEASIBILITY OF A MULTI-INSTITUTIONAL PHASE II TRIAL INCOPORATING BIOPSY AND MOLECULARLY DETERMINED TREATMENT OF CHILDREN AND YOUNG ADULTS WITH NEWLY DIAGNOSED DIFFUSE INTRINSIC PONTINE GLIOMAS (DIPG). (2016) (0)
- HGG-51. Uncovering therapeutic vulnerabilities in mismatch repair-deficient gliomas (2022) (0)
- Author Correction: Molecular subtypes of diffuse large B cell lymphoma are associated with distinct pathogenic mechanisms and outcomes (2018) (0)
- Abstract A44: Functional models of chromosome arm-level aneuploidies in cancer (2020) (0)
- SNP array based analyses of somatic genetic and the identification of MITF as a lineage survival oncogene amplified in malignant melanoma (0)
- Correction: Inferring Loss-of-Heterozygosity from Unpaired Tumors Using High-Density Oligonucleotide SNP Arrays (2007) (0)
- HG-73SAFETY AND FEASIBILITY OF A MULTI-INSTITUTIONAL PHASE II TRIAL INCOPORATING BIOPSY AND MOLECULARLY DETERMINED TREATMENT OF CHILDREN AND YOUNG ADULTS WITH NEWLY DIAGNOSED DIFFUSE INTRINSIC PONTINE GLIOMAS (DIPG). (2016) (0)
- Glioma Through the Looking GLASS: the Glioma Longitudinal Analysis consortium, molecular evolution of diffuse gliomas (2017) (0)
- Abstract 4369: Genome-wide copy number dependency analysis identifies partial copy loss of SF3B1 as a novel cancer vulnerability (2016) (0)
- Early TP53 alterations engage environmental exposures to promote gastric premalignancy in an integrative mouse model (2020) (0)
- PATH-30. GENOMIC LANDSCAPE OF CENTRAL NERVOUS SYSTEM TUMORS (2017) (0)
- Histone-mutant interneuron progenitors co-opt PDGFRA for gliomagenesis (2020) (0)
- Author Correction: Patterns of somatic structural variation in human cancer genomes (2020) (0)
- 20/#1057 Integrated profiling of a prospective endometrial cancer organoid biobank reveals high heterogeneity (2022) (0)
- DDDR-22. TRANSLATION OF THE PDGFRA/KIT INHIBITOR AVAPRITINIB FOR PEDIATRIC HIGH-GRADE GLIOMA (2022) (0)
- PATH-16. EVALUATION OF SEX-BASED DIFFERENCES IN CLINICAL OUTCOMES AND TUMOR GENOMICS IN PATIENTS WITH NEWLY DIAGNOSED IDH-WILDTYPE GLIOBLASTOMA RECEIVING CHEMORADIATION (2021) (0)
- Abstract IA8: Genetic approaches to cancer (2012) (0)
- LGG-45. Genetic dependencies inMYB/MYBL1-driven pediatric low-grade glioma models (2022) (0)
- Author Correction: Patterns of somatic structural variation in human cancer genomes (2020) (0)
- DDRE-14. OPTIMIZING MDM2 INHIBITION FOR THE TREATMENT OF HIGH-GRADE GLIOMA (2021) (0)
- Cancer Vulnerabilities Unveiled by Genomic Loss Citation (2012) (0)
- Abstract 4974: Pharmacogenomic interactions in glioblastoma cell line models (2017) (0)
- Comprehensivemolecularcharacterization of human colon and rectal cancer (2012) (0)
- Abstract 214: Genetic and transcriptional instability alters cell line drug response (2018) (0)
- Author Correction: Targeting wild-type KRAS-amplified gastroesophageal cancer through combined MEK and SHP2 inhibition (2018) (0)
- HGG-60. Structural variants shape driver combinations and outcomes in pediatric high-grade glioma (2022) (0)
- RARE-07. THE LANDSCAPE OF GENOMIC ALTERATIONS IN ADAMANTINOMATOUS CRANIOPHARYNGIOMAS (2020) (0)
- Publisher Correction: Molecular subtypes of diffuse large B cell lymphoma are associated with distinct pathogenic mechanisms and outcomes (2018) (0)
- Author Correction: Analyses of non-coding somatic drivers in 2,658 cancer whole genomes (2020) (0)
- Study of genetic alterations in soft tissue sarcomas by SNP arrays, expression profiling and high-throughput sequencing (2007) (0)
- Abstract PL07-01: Molecular profiling of breast cancer in Mexico: Identification of novel therapeutic targets through whole genome sequencing analysis. (2012) (0)
- Integrative Copy Number and Mutational Analysis Improves Glioma Diagnostics (2014) (0)
- High-Resolution Mapping of Structural Mutations in Prostate Cancer With Single Nucleotide Polymorphism Arrays (2005) (0)
- MEDU-37. NEURONAL DIFFERENTIATION AND CELL-CYCLE PROGRAMS MEDIATE RESPONSE AND RESISTANCE TO BET-BROMODOMAIN INHIBITION IN MYC-DRIVEN MEDULLOBLASTOMA (2019) (0)
- [Correspondence] Breast-cancer stromal cells with TP53 mutations (2008) (0)
- Abstract 3002: Genome engineering approaches to generate models of chromosome arm-level cancer aneuploidy (2018) (0)
- Germline variation contributes to false negatives in CRISPR-based experiments with varying burden across ancestries (2022) (0)
- Author Correction: Patterns of somatic structural variation in human cancer genomes (2020) (0)
- Oncogenesis and Colon Exhibit Distinct Patterns of Genome Instability and Gastrointestinal Adenocarcinomas of the Esophagus, Stomach, (2012) (0)
- Haplotype-resolved germline and somatic alterations in renal medullary carcinomas (2021) (0)
- Application of a robust and novel ex vivo platform mimicking patient heterogenous tumor microenvironment for personalized cancer treatment. (2015) (0)
- Interrogating the Role of Chromatin Regulator BRD4 in the DNA Damage Response in Medulloblastoma (2019) (0)
- Phase I Trial of Vandetanib Plus Sirolimus in Adults with Recurrent Glioblastoma (P04.180) (2012) (0)
- Author Correction: Inferring structural variant cancer cell fraction (2022) (0)
- Next-Generation Sequencing of Sporadic Schwannomas Reveals Critical Importance of NF2 Alteration (2016) (0)
- Abstract A103: High-throughput genomic and chemical screening in glioblastoma cell lines. (2013) (0)
- Abstract SY25-03: Haploinsufficiency in cancer: When half simply isn't good enough. (2013) (0)
- Abstract 2135: Functional models of chromosome arm aneuploidies in lung squamous cell carcinoma (2021) (0)
- Inferring Loss-of-Heterozygosity from Tumors Without Paired Normals Using High-Density SNP Arrays (2005) (0)
- INNV-40. REAL WORLD INTEGRATION OF THE NEUROLOGIC ASSESSMENT IN NEURO-ONCOLOGY (NANO) SCALE IN CLINICAL PRACTICE IN PATIENTS WITH IDH-WT GBM (2021) (0)
- A Structural Basis for p53-Deficiency, Deregulated Cell Cycle and Unfavorable Outcome in Diffuse Large B-Cell Lymphoma (2012) (0)
- LGG-35. FUNCTIONAL GENOMIC APPROACHES TO IDENTIFY THERAPEUTIC TARGETS IN MYB AND MYBL1 EXPRESSING PEDIATRIC LOW-GRADE GLIOMAS (2020) (0)
- CTIM-25. NEOADJUVANT ANTI-PD1 IMMUNOTHERAPY FOR SURGICALLY ACCESSIBLE RECURRENT GLIOBLASTOMA: CLINICAL AND MOLECULAR OUTCOMES OF A STAGE 2 SINGLE-ARM EXPANSION COHORT (2022) (0)
- MEDU-36. BCL2 FAMILY MEMBERS ATTENUATE RESPONSE OF MYC-DRIVEN MEDULLOBLASTOMAS TO BET-BROMODOMAIN INHIBITION (2019) (0)
- OS10.1 Genomic landscape of pituitary adenomas. (2017) (0)
- EXTH-19. OPTIMIZING MDM2 INHIBITION FOR THE TREATMENT OF GLIOBLASTOMA (2022) (0)
- Abstract 2027: MECP2 is a frequently amplified oncogene with an unusual epigenetic mechanism of action (2015) (0)
- Supplementary Material 8 (2013) (0)
- Comprehensivegenomiccharacterization of squamous cell lung cancers (2012) (0)
- Abstract LB-227: Truncal activating MAPK and PI3K pathway alterations and exceptional response to dual pathway inhibition in anaplastic thyroid cancer (2016) (0)
- BIOL-04. INTEGRATED COPY-NUMBER AND CANCER DEPENDENCY ANALYSIS REVEALS ALTERED SPLICEOSOME STOICHIOMETRY AS A NOVEL VULNERABILITY IN GENOMICALLY DISRUPTED CANCERS (2017) (0)
- OMRT-6. Optimizing MDM2 inhibition for the treatment of high-grade glioma (2021) (0)
- LGG-04. CLINICO-HISTO-MOLECULAR LANDSCAPE OF EIGHTY-TWO PEDIATRIC AND YOUNG ADULT DYSEMBRYOPLASTIC NEUROEPITHELIAL TUMORS (2019) (0)
- Single nucleotide polymorphism microarrays in the analysis of cancer (2009) (0)
- hypermutability with distinct patterns of DNA breakage and rearrangement-induced Somatic rearrangements across cancer reveal classes of samples Material Supplemental (2013) (0)
- Abstract B66: Identification of genetic and non-genetic dependencies in glioblastoma cell lines targeted by small molecules (2015) (0)
- Author Correction: Inferring structural variant cancer cell fraction (2022) (0)
- Abstract B18: Modeling renal medullary carcinomas identifies druggable vulnerabilities in SMARCB1-deficient cancers (2018) (0)
- The evolutionary history of 2,658 cancers (2020) (0)
- The UTX Tumor Suppressor Directly Senses Oxygen to Control Chromatin and Cell Fate (2019) (0)
- DIPG-02. TRANSLATIONAL MR IMAGING CORRELATES FOR MOLECULAR ANALYSES IN DIFFUSE INTRINSIC PONTINE GLIOMA (DIPG) (2019) (0)
- Interim Analysis of a Randomized Placebo-Controlled Pilot Trial of Armodafinil for Fatigue in Patients with Malignant Gliomas Undergoing Radiotherapy with or without Standard Chemotherapy Treatment (P07.104) (2012) (0)
- LG-47TYPE II RAF INHIBITORS INHIBIT BRAF MUTATIONS AND TRUNCATED FUSIONS IN PEDIATRIC LOW-GRADE GLIOMAS (2016) (0)
- Abstract 4727: Genomic characterization of brain metastases reveals divergent evolution and metastasis specific mutations (2015) (0)
- DIPG-53. CHARACTERIZING THE ROLE OF PPM1D MUTATIONS IN THE PATHOGENESIS OF DIFFUSE INTRINSIC PONTINE GLIOMAS (DIPGS) (2020) (0)
- Loss of heterozygosity of essential genes represents a widespread class of potential cancer vulnerabilities (2020) (0)
- Toxicity, Hospitalization Burden, and Survival Among Glioblastoma Patients Receiving Chemoradiation (2014) (0)
- Abstract LB-26: A mathematical methodology for determining the temporal order of pathway alterations in cancer (2011) (0)
- Title MECP 2 Is a Frequently Amplified Oncogene with a Novel Epigenetic Mechanism that Mimics the Role of Activated RAS in Malignancy Authors / Affiliation (2017) (0)
- Abstract 803: Genomic sequencing of meningiomas reveals oncogenic SMO and AKT1 mutations. (2013) (0)
- Author Correction: The evolutionary history of 2,658 cancers (2023) (0)
- Cell Reports Resource The Cancer Genome Atlas Comprehensive Molecular Characterization of Renal Cell Carcinoma (2018) (0)
- LGG-58. Understanding the transcriptional heterogeneity of pediatric low-grade gliomas and its implication for tumor pathophysiology (2022) (0)
- Abstract B46: The long noncoding RNA INCA1 is a novel regulator of PD-L1 expression in tumors (2020) (0)
- High Resolution SNP Arrays Identify Amplified Regions in Lung Cancer (2005) (0)
- DRES-08. CLINICAL SIGNIFICANCE OF HYPERMUTATION IN GLIOMAS (2019) (0)
- Patterns of structural variation define prostate cancer across disease states (2022) (0)
- Cas9 activates the p53 pathway and selects for p53-inactivating mutations (2020) (0)
- AT-36PANOBINOSTAT IN COMBINATION WITH BEVACIZUMAB FOR RECURRENT GLIOBLASTOMA AND ANAPLASTIC GLIOMA (2014) (0)
- HGG-32. UNCOVERING THERAPEUTIC VULNERABILITIES IN MISMATCH REPAIR-DEFICIENT GLIOMAS (2020) (0)
- LGG-05. SINGLE CELL RNA SEQUENCING REVEALS MITOGENIC AND PROGENITOR GENE PROGRAMS IN BRAF-REARRANGED PILOCYTIC ASTROCYTOMAS (2019) (0)
- LG-001. OPTIC PATHWAY GLIOMAS; FROM CHILDHOOD TO ADULTHOOD (2014) (0)
- DIPG-12. CHARACTERIZING THE ROLE OF PPM1D MUTATIONS IN THE PATHOGENESIS OF DIFFUSE INTRINSIC PONTINE GLIOMAS (DIPGs) (2019) (0)
- PPM1D mutations are oncogenic drivers of de novo diffuse midline glioma formation (2022) (0)
- Integrated genomic characterization of oesophageal carcinoma (2017) (0)
- Genomic Landscape of Pituitary Adenomas (2016) (0)
- Molecular subtypes of diffuse large B cell lymphoma are associated with distinct pathogenic mechanisms and outcomes (2018) (0)
- CTNI-40. EVALUATING FEASIBILITY AND EFFICIENCY OF PHASE II ADAPTIVE PLATFORM TRIAL DESIGNS BASED ON THE INDIVIDUALIZED SCREENING TRIAL OF INNOVATIVE GLIOBLASTOMA THERAPY (INSIGhT) EXPERIENCE (2021) (0)
- INNV-22. LIQUID BIOPSY DETECTION OF GENOMIC ALTERATIONS IN PEDIATRIC BRAIN TUMORS FROM CELL FREE DNA IN PERIPHERAL BLOOD, CSF, AND URINE (2018) (0)
- Abstract 2710: Associations between structural variant signatures and drug sensitivity in cell lines (2022) (0)
- LGG-13. RESOLVING TRANSCRIPTIONAL PROFILES IN BRAF-REARRANGED PILOCYTIC ASTROCYTOMA USING SINGLE CELL RNA SEQUENCING (2018) (0)
- ACTR-93. A PHASE I STUDY OF MLN0128 (TAK-228) AND BEVACIZUMAB IN PATIENTS WITH ADVANCED SOLID TUMORS INCLUDING GLIOBLASTOMA (2017) (0)
- Author Correction: Cas9 activates the p53 pathway and selects for p53-inactivating mutations (2020) (0)
- PATH-03. CLINICAL UTILITY OF NEXT GENERATION SEQUENCING IN IDH-WILDTYPE GLIOBLASTOMA: THE DANA-FARBER CANCER INSTITUTE EXPERIENCE (2020) (0)
- Selective and mechanistic pressures shaping cancer aneuploidies (2021) (0)
- Abstract 5719: Clinical response to the PDGFRα inhibitor avapritinib in high-grade glioma patients (2023) (0)
- Title: Genomic heterogeneity and exceptional response to dual pathway inhibition in anaplastic thyroid cancer Authors: (2016) (0)
- Inferring structural variant cancer cell fraction (2020) (0)
- Abstract 2173: Ancestry bias in CRISPR guide design impedes discovery of genetic dependencies (2022) (0)
- PATH-35. A SCALABLE MOLECULARLY INTEGRATED CLASSIFIER FOR MENINGIOMA OUTPERFORMS WHO CLASSIFICATION (2020) (0)
- Neutral tumor evolution? (2018) (0)
- DRES-05. MOLECULAR EVOLUTION OF DIFFUSE GLIOMAS AND THE GLIOMA LONGITUDINAL ANALYSIS CONSORTIUM (2018) (0)
- Genetic Alterations in Skull Base Meningiomas (2015) (0)
- Supplementary Material 12 (2015) (0)
- Supplementary Material 18 (2014) (0)
- Neuropathology and Ophthalmic Pathology (2016) (0)
- TBIO-18. LIQUID BIOPSY DETECTION OF GENOMIC ALTERATIONS IN PEDIATRIC BRAIN TUMORS FROM CELL FREE DNA IN PERIPHERAL BLOOD, CSF, AND URINE (2018) (0)
- Genomic Characterization of Meningiomas (2012) (0)
- CTNI-26. SURGICAL WINDOW OF OPPORTUNITY TRIAL OF NAVTEMADLIN (KRT 232; AMG232) IN PATIENTS WITH RECURRENT GLIOBLASTOMA (2022) (0)
- Preliminary Data from a Multicenter, Phase II, Randomized, Non-Comparative Clinical Trial of Radiation and Temozolomide with or without Vandetanib in Newly-Diagnosed Glioblastoma (GBM) (S45.006) (2012) (0)
- BIOM-47. PREDICTORS OF SEIZURE AT ONSET USING A FUNCTIONAL VARIANT ANALYSIS OF TARGETED NEXT GENERATION SEQUENCING IN GBM (2022) (0)
- Abstract B077: Comprehensive molecular characterization and high-throughput chemical screening identifies genetic dependencies and molecular vulnerabilities in glioblastoma cell line models (2018) (0)
- Corrigendum: Recurrent hormone-binding domain truncated ESR1 amplifications in primary endometrial cancers suggest their implication in hormone independent growth (2016) (0)
- EXTH-95. UNCOVERING THERAPEUTIC VULNERABILITIES IN MISMATCH REPAIR-DEFICIENT GLIOMAS (2022) (0)
- PATH-16. MOLECULAR PATHOLOGY AND CLINICAL CHARACTERISTICS OF MMR DEFICIENCY (MMRd) IN DIFFUSE GLIOMAS (2018) (0)
- GENO-09LANDSCAPE OF GENOMIC ALTERATIONS IN PITUITARY ADENOMAS (2015) (0)
- Abstract 5559: Proteomic identification of activated, essential tyrosine kinases in human cancers (2010) (0)
- Genomic evolution of cancer models: perils and opportunities (2018) (0)
- Erratum: Genomic landscape of high-grade meningiomas (2017) (0)
- Medulloblastoma models which harbor amplifications of myc family members are sensitive to BET-Bromodomain inhibition (2014) (0)
- LGG-05. SINGLE-CELL RNA SEQUENCING OF PEDIATRIC LOW-GRADE GLIOMAS REVEALS INTRATUMORAL HETEROGENEITY. (2017) (0)
- Abstract 13: Chemical genomics identifies MCL1 repressors and resistance mechanism (2011) (0)
- LGG-06. FUNCTIONAL AND THERAPEUTIC RELEVANCE OF MYB-QKI-INDUCED TRANSCRIPTIONAL EVENTS TO GLIOMAGENESIS. (2017) (0)
- Acknowledgment of Reviewers, 2019 (2019) (0)
- TMOD-14. A PATIENT-DERIVED CANCER CELL LINE ATLAS OF PRIMARY AND METASTATIC CENTRAL NERVOUS SYSTEM TUMORS (2018) (0)
- Abstract 3647: Single cell RNA sequencing reveals mitogenic and progenitor gene programs inBRAF-rearranged pilocytic astrocytomas (2019) (0)
- Longitudinal molecular trajectories of diffuse glioma in adults (2019) (0)
- RARE-22 Characterizing the landscape of structural variants in adamantinomatous craniopharyngioma (2022) (0)
- ALK amplification and rearrangements are recurrent targetable events in congenital and adult glioblastoma. (2023) (0)
- Proliferative Potential Recurrent Hemizygous Deletions in Cancers May Optimize (2012) (0)
- HER-2/neu expression is associated with increased tumor cell proliferation, loss of hormone receptors and an aggressive phenotype in a population based setting of endometrial carcinomas (2007) (0)
- Key Word and Full-Text Search Genomic Characterization of Meningiomas (2019) (0)
- LGG-59. Identifying hidden drivers of low-grade glioma tumor growth (2022) (0)
- TRTH-15. RESISTANCE MECHANISMS TO BET-BROMODOMAIN INHIBITION IN MYC-AMPLIFIED MEDULLOBLASTOMA (2017) (0)
- THER-22. BROMODOMAIN INHIBITORS INDUCE DOWNREGULATION OF DNA DAMAGE REPAIR PATHWAYS AND OFFER NOVEL SYNERGISTIC COMBINATIONS WITH ENHANCED SAFETY PROFILES FOR THE TREATMENT OF MEDULLOBLASTOMA AND GLIOBLASTOMA (2019) (0)
- Author Correction: Retrospective evaluation of whole exome and genome mutation calls in 746 cancer samples (2020) (0)
- Abstract 5135: Analysis of formalin-fixed paraffin-embedded (FFPE) samples. (2013) (0)
- EPCO-21. CORE REGULATORY CIRCUIT TRANSCRIPTION FACTORS DRIVE EXPRESSION FROM HIGH LEVEL AMPLICONS IN PEDIATRIC HIGH-GRADE GLIOMAS (2021) (0)
- Supplementary Material 16 (2012) (0)
- Genomic Landscape and Immunological Profile of Glioblastoma in East Asian Patients (2021) (0)
- Corrigendum: Recurrent hormone-binding domain truncated ESR1 amplifications in primary endometrial cancers suggest their implication in hormone independent growth (2017) (0)
- Abstract 1166: Leveraging existing data to identify ancestry-associated features across multiple cancer types (2022) (0)
- Integrative whole-genome copy number analysis and mutation profiling of FFPE brain tumor specimens and potential in designing multi-arm clinical trials. (2014) (0)
- DIPG-54. p53 pathway reactivation as a therapeutic strategy in diffuse intrinsic pontine glioma (2022) (0)
- MODL-38. DEVELOPMENTAL EFFECTS OF MYBL1 ACTIVATION ON MURINE BRAIN AND GLIAL DEVELOPMENT (2022) (0)
- PATH-15. THE PROGNOSTIC IMPLICATION OF MGMT PROMOTER METHYLATION IN IDH-MUTANT GLIOMAS (2022) (0)
This paper list is powered by the following services:
What Schools Are Affiliated With Rameen Beroukhim?
Rameen Beroukhim is affiliated with the following schools:
